帕金森氏症：全球市場（2011∼2021年）

帕金森氏症：全球市場（2011∼2021年） 是由出版商Visiongain在2011年09月所出版的。 這份英文市場調查報告書包含142 Pages 價格從美金2642起跳。

簡介

本報告為，調查分析帕金森氏症市場，並匯整市場收益、2021年止預測、市場佔有率、SWOT分析等定性分析、研發趨勢，以下列摘要形式闡述。

第1章 實施概要

第2章 2011年之帕金森氏症：科學性、臨床性概要

• 帕金森氏症具有多巴胺減少之特徵
• 意識、行為、其他症狀
• 認為是子類型之發生來源
• 療程

第3章 全球帕金森氏症市場：2011∼2021年

• 市場概要
• 市場簡介
• 多巴胺激動劑：目前市場重心
  • 市場預測：2011∼2021年
• 多巴胺激動劑：帕金森氏症之商業等級
  • 市場預測：2011∼2021年
• COMT抑製劑
  • 市場預測：2011∼2021年
• MAO抑製劑
  • 市場預測：2011∼2021年
• 其他
  • 市場預測：2011∼2021年

第4章 主要產品

• 4種藥劑牽引市場
• Stalevo及Comtess
• Sifrol
• Azilect
• Requip
• 其他
  • 銷售預測：2011∼2021年

第5章 主要國家市場

• 美國：最大市場
• 美國市場預測：2011∼2021年
• 歐洲5國市場預測：2011∼2021年
• 日本市場預測：2011∼2021年
• 中國市場預測：2011∼2021年
• 印度市場預測：2011∼2021年
• 其他

第6章 帕金森氏症之治療：研發產品線（2011年）

• 2011年有超過300個後期臨床實驗正在進行
• KW-6002及其他腺苷受體拮抗劑
• Safinamide：多巴胺激動劑及非激動劑兩方之效果
• Fipamezole
• Coenzyme Q10
• 基因治療
• CERE-120
• Neurologix：又一基因治療之候補
• 疾病症狀減緩治療

第7章 主要企業

• Boehringer Ingelheim
• Novartis
• Orion
• Teva Pharmaceutical Industries
• GlaxoSmithKline
• Impax Laboratories
• Kyowa Hakko Kirin
• Merck Serono
• Newron
• Ceregene
• Neurologix
• Santhera
• Biotie
• Merck & Co
• Xenoport

第8章 定性分析

第9章 專家訪談

第10章 結論

圖表

目錄

What are the commercial prospects for the treatment of Parkinson's disease? Visiongain's report shows you potential drug revenues to 2021. Find opportunities and forecasts.

Do you want revenue predictions for Parkinson's disease treatments at total world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions.

Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can perform to 2021, seeing potential revenues. We cover revenues for dopaminergic agents, dopamine agonists, COMT inhibitors, MAO inhibitors and other drugs for Parkinson's disease.

We discuss Boehringer Ingelheim, Novartis, GSK, Teva and many other companies. Receive industry and market information you need.

The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress. Find R&D trends.

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 114 tables and charts and two research interviews (see the table of contents).

Advantages of Parkinson's Disease: World Drug Market 2011-2021 for your work

Our report gives you the following advantages in particular:

• Find revenue predictions to 2021 for the world Parkinson's disease drug market and submarkets, seeing revenue growth
• Discover revenue forecasts to 2021 for leading products, assessing market potentials
• Assess leading companies, discovering their activities and prospects
• See revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
• Review R&D for treating Parkinson's disease, seeing pipeline trends
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• View opinion from our survey, receiving detailed interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on Parkinson's disease, helping you to stay ahead.

Gain industry and market analysis for Parkinson's disease treatment now

Our report is for everybody needing industry and market analysis for Parkinson's disease treatments. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government.

1. Executive Summary

• 1.1. Parkinson's Disease: Market Overview
• 1.2. Contents of this Report
• 1.3. Research and Analysis Methods

2. Parkinson's Disease in 2011: A Scientific and Clinical Overview

• 2.1. Parkinson's is Characterised by Dopamine Depletion
• 2.2. Motor Symptoms of Parkinson's Disease
  • 2.2.1. Tremor
  • 2.2.2. Rigidity
  • 2.2.3. Bradykinesia
  • 2.2.4. Postural Instability
  • 2.2.5. Other Motor Symptoms
• 2.3. Cognitive, Behavioural and Other Symptoms
  • 2.3.1. Cognitive Deficits
  • 2.3.2. Behavioural and Mood Difficulties
  • 2.3.3. Other Symptoms
• 2.4. Subtypes and Possible Origin of the Disease
• 2.5. Timeline of Parkinson's Disease Treatment

3. The Global Market for Parkinson's Disease Drugs 2011-2021

• 3.1. The Parkinson's Disease Market: Overview 2011-2021
• 3.2. The Parkinson's Disease Market: Breakdown 2011-2021
• 3.3. Dopaminergic Agents: Still Key to the Market
  • 3.3.1. Dopaminergic Agents: Market Forecast 2011-2021
• 3.4. Dopamine Agonists: The Foremost Commercial Class of Parkinson's Drugs
  • 3.4.1. Dopamine Agonists: Market Forecast 2011-2021
• 3.5. COMT Inhibitors: The Best-Selling Class in the Parkinson's Drug Market
  • 3.5.1. COMT Inhibitors: Market Forecast 2011-2021
• 3.6. MAO Inhibitors: The Fastest-Growing Market Sector
  • 3.6.1. MAO Inhibitors: Market Forecast 2011-2021
• 3.7. Other Classes of Parkinson's Disease Treatment
  • 3.7.1. Other Classes of Parkinson's Disease Treatment: Market Forecast 2011-2021

4. Leading Products in the Parkinson's Disease Treatment Market

• 4.1. Four Drugs Lead the Market
• 4.2. Stalevo and Comtess (Orion/Novartis)
  • 4.2.1. Stalevo and Comtess: Sales Forecast 2011-2021
• 4.3. Sifrol (Boehringer Ingelheim)
  • 4.3.1. Sifrol: Sales Forecast 2011-2021
• 4.4. Azilect (Teva Pharmaceuticals)
  • 4.4.1. Azilect: Sales Forecast 2011-2021
• 4.5. Requip (GlaxoSmithKline)
  • 4.5.1. Requip: Sales Forecast 2011-2021
• 4.6. Other Products
  • 4.6.1. Other Products: Market Forecast 2011-2021

5. Leading National Markets for Parkinson's Treatments 2011-2021

• 5.1. The US is the Largest Market
• 5.2. The US: Market Forecast 2011-2021
• 5.3. The EU5: Market Forecasts 2011-2021
• 5.4. Japan: Market Forecast 2011-2021
• 5.5. China: Market Forecast 2011-2021
• 5.6. India: Market Forecast 2011-2021
• 5.7. Rest of the World: Market Forecast 2011-2021

6. Parkinson's Disease Treatments: R&D Pipeline Analysis 2011

• 6.1. There are More than 300 Late-Stage Trials of Parkinson's Drugs in Progress in 2011
• 6.2. KW-6002 (Kyowa Hakko Kirin) and Other Adenosine Receptor Antagonists
• 6.3. Safinamide (Merck Serono): Both Dopaminergic and Non-dopaminergic Effects?
• 6.4. Fipamezole (Santhera Pharmaceuticals)
• 6.5. Coenzyme Q10 (National Institute of Neurological Disorders and Stroke [NINDS], and Others)
• 6.6. Potential Gene Therapies
• 6.7. CERE-120 (Ceregene): Lead Gene-Therapy Product
• 6.8. Neurologix: Another Gene Therapy Candidate
• 6.9. Possible Disease-Modifying Treatments

7. Top Companies in the Parkinson's Disease Treatments Market 2011

• 7.1. Boehringer Ingelheim
• 7.2. Novartis
• 7.3. Orion
• 7.4. Teva Pharmaceutical Industries
• 7.5. GlaxoSmithKline
• 7.6. Impax Laboratories
• 7.7. Kyowa Hakko Kirin
• 7.8. Merck Serono
• 7.9. Newron
• 7.10. Ceregene
• 7.11. Neurologix
• 7.12. Santhera
• 7.13. Biotie
• 7.14. Merck & Co
• 7.15. Xenoport

8. Parkinson's Treatment Market: Qualitative Analysis

• 8.1. Strengths: Parkinson's Disease is a Widely Prevalent and Treatable Disease
• 8.2. Weaknesses: Products on the Market Have Limitations and Can Be Superseded
• 8.3. Opportunities: Neurodegenerative Disorder Treatments Are a Fertile R&D Area
• 8.4. Threats: New Parkinson's Treatments May Be Subject to Political, Commercial and Social Pressures

9. Research Interviews from Our Survey

• 9.1. Interview with Dr Kieran Breen
  • 9.1.1. On Current Treatment Options for Parkinson's Disease
  • 9.1.2. On Prospective New Drugs
  • 9.1.3. On Cell Death and Neuroprotection
  • 9.1.4. On Braak's Hypothesis and Parkinson's Disease Progression
  • 9.1.5. On Disease Heterogeneity and Potential Biomarkers
  • 9.1.6. On Growth Factors, Gene Therapies and Stem Cells
  • 9.1.7. On Brain-Banking and Animal Models
• 9.2. Interview with Professor Rammohan Rao
  • 9.2.1. On the Role of the Endoplasmic Reticulum in Cell Death
  • 9.2.2. On Therapeutic Applications of That Research
  • 9.2.3. On Challenges in the Parkinson's Disease Field in 2011

10. Conclusions from Our Study

• 10.1. Parkinson's Disease Treatment Market to 2021
• 10.2. A Promising But Unproven Pipeline
• 10.3. Other Factors Will Benefit the Parkinson's Disease Treatment Market

• Table 2.1: Timeline of Parkinson's Disease
• Table 3.1: Parkinson's Disease Drug Market: Total World Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.2: Parkinson's Disease Drug Market: Total World Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.3: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2010
• Table 3.4: Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 3.5: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2015
• Table 3.6: Parkinson's Disease Drug Market, Breakdown by Mechanism of Action: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 3.7: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2021
• Table 3.8: Dopaminergic Agents: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.9: Dopaminergic Agents: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.10: Dopamine Agonists: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.11: Dopamine Agonists: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.12: COMT Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.13: COMT Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.14: MAO Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.15: MAO Inhibitors: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 3.16: Other Parkinson's Treatments: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 3.17: Other Parkinson's Treatments: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 4.1: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2010
• Table 4.2: Leading Parkinson's Disease Drugs: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 4.3: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2015
• Table 4.4: Leading Parkinson's Disease Drugs: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 4.5: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2021
• Table 4.6: US Patent Expiry Dates for Leading Parkinson's Disease Drugs, 2008-2017
• Table 4.7: Stalevo & Comtess Revenues: Breakdown by Company, 2010
• Table 4.8: Stalevo & Comtess: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 4.9: Stalevo & Comtess: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 4.10: Sifrol: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 4.11: Sifrol: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 4.12: Azilect: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 4.13: Azilect: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 4.14: Requip: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 4.15: Requip: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 4.16: Other Products Approved for Parkinson's Disease Treatment, 2011
• Table 4.17: Other Products: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 4.18: Other Products: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.1: Leading National Markets: Revenues ($m), Market Shares (%), 2010
• Table 5.2: Leading National Markets: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.3: Leading National Markets: Revenues ($m), Market Shares (%), 2015
• Table 5.4: Leading National Markets: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.5: Leading National Markets: Revenues ($m), Market Shares (%), 2021
• Table 5.6: US Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.7: US Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.8: EU5 Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.9: EU5 Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.10: EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2010
• Table 5.11: EU5 Market: National Breakdown, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
• Table 5.12: EU5 Market: National Breakdown, Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
• Table 5.13: EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2021
• Table 5.14: Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.15: Japanese Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.16: Chinese Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.17: Chinese Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.18: Indian Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.19: Indian Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 5.20: Rest of the World Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
• Table 5.21: Rest of the World Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
• Table 6.1: Some Key Products in the Late-Stage Pipeline, 2011
• Table 8.1: Strengths, Weaknesses, Opportunities and Threats in the Parkinson's Drug Market, 2011

• Figure 2.1: The Five Stages of Parkinson's Disease
• Figure 3.1: Parkinson's Disease Drug Market: Total World Revenues ($m), 2010-2015
• Figure 3.2: Parkinson's Disease Drug Market: Total World Revenues ($m), 2016-2021
• Figure 3.3: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2010
• Figure 3.4: Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), 2010-2015
• Figure 3.5: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2015
• Figure 3.6: Parkinson's Disease Drug Market: Breakdown by Mechanism of Action, Revenues ($m), 2016-2021
• Figure 3.7: Parkinson's Disease Market Breakdown by Mechanism of Action: Revenues ($m), Market Shares (%), 2021
• Figure 3.8: Dopaminergic Agents: Revenues ($m), 2010-2015
• Figure 3.9: Dopaminergic Agents: Revenues ($m), 2016-2021
• Figure 3.10: Dopamine Agonists: Revenues ($m), 2010-2015
• Figure 3.11: Dopamine Agonists: Revenues ($m), 2016-2021
• Figure 3.12: COMT Inhibitors: Revenues ($m), 2010-2015
• Figure 3.13: COMT Inhibitors: Revenues ($m), 2016-2021
• Figure 3.14: MAO Inhibitors: Revenues ($m), 2010-2015
• Figure 3.15: MAO Inhibitors: Revenues ($m), 2016-2021
• Figure 3.16: Other Parkinson's Treatments: Revenues ($m), 2010-2015
• Figure 3.17: Other Parkinson's Treatments: Revenues ($m), 2016-2021
• Figure 4.1: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2010
• Figure 4.2: Leading Parkinson's Disease Drugs: Revenues ($m), 2010-2015
• Figure 4.3: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2015
• Figure 4.4: Leading Parkinson's Disease Drugs: Revenues ($m), 2016-2021
• Figure 4.5: Leading Parkinson's Disease Drugs: Revenues ($m), Market Shares (%), 2021
• Figure 4.6: Stalevo & Comtess Revenues: Breakdown by Company, 2010
• Figure 4.7: Stalevo & Comtess: Revenues ($m), 2010-2015
• Figure 4.8: Stalevo & Comtess: Revenues ($m), 2016-2021
• Figure 4.9: Sifrol: Revenues ($m), 2010-2015
• Figure 4.10: Sifrol: Revenues ($m), 2016-2021
• Figure 4.11: Azilect: Revenues ($m), 2010-2015
• Figure 4.12: Azilect: Revenues ($m), 2016-2021
• Figure 4.13: Requip: Revenues ($m), 2010-2015
• Figure 4.14: Requip: Revenues ($m), 2016-2021
• Figure 4.15: Other Products: Revenues ($m), 2010-2015
• Figure 4.16: Other Products: Revenues ($m), 2016-2021
• Figure 5.1: Leading National Markets: Revenues ($m), Market Shares (%), 2010
• Figure 5.2: Leading National Markets: Revenues ($m), 2010-2015
• Figure 5.3: Leading National Markets: Revenues ($m), Market Shares (%), 2015
• Figure 5.4: Leading National Markets: Revenues ($m), 2016-2021
• Figure 5.5: Leading National Markets: Revenues ($m), Market Shares (%), 2021
• Figure 5.6: US Market: Revenues ($m), 2010-2015
• Figure 5.7: US Market: Revenues ($m), 2016-2021
• Figure 5.8: EU5 Market: Revenues ($m), 2010-2015
• Figure 5.9: EU5 Market: Revenues ($m), 2016-2021
• Figure 5.10: EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2010
• Figure 5.11: EU5 Market: National Breakdown, Revenues ($m), 2010-2015
• Figure 5.12: EU5 Market: National Breakdown, Revenues ($m), 2016-2021
• Figure 5.13: EU5 Market: National Breakdown, Revenues ($m), Market Shares (%), 2021
• Figure 5.14: Japanese Market: Revenues ($m), 2010-2015
• Figure 5.15: Japanese Market: Revenues ($m), 2016-2021
• Figure 5.16: Chinese Market: Revenues ($m), 2010-2015
• Figure 5.17: Chinese Market: Revenues ($m), 2016-2021
• Figure 5.18: Indian Market: Revenues ($m), 2010-2015
• Figure 5.19: Indian Market: Revenues ($m), 2016-2021
• Figure 5.20: Rest of the World Market: Revenues ($m), 2010-2015
• Figure 5.21: Rest of the World Market: Revenues ($m), 2016-2021

• Acadia Pharmaceuticals
• Amgen
• Axxonis Pharma
• Biotie
• BioSante Pharmaceuticals
• Biovail
• Boehringer Ingelheim
• Brainstorm Cell Therapeutics
• Buck Institute for Research on Aging
• Ceregene
• Chelsea Therapeutics
• Ciba-Geigy
• Cipla
• Columbia University
• Dainippon Sumitomo
• Dresden University of Technology
• Eisai
• EMEA/EMA
• Endo Pharmaceuticals
• Erba
• Farmitalia Carlo
• FDA [US]
• Impax Laboratories
• GlaxoSmithKline
• Ipsen
• Juvantia Pharma
• Kaneka Nutrients
• Kyowa Hakko Kirin
• Lundbeck
• Maypro Industries
• Merck & Co.
• Merck KGaA
• Merck Serono
• Mitsubishi Gas Chemical
• Mylan
• National Institute of Neurological Disorders and Stroke [NINDS]
• Neupro
• Neurologix
• Newron Pharmaceuticals
• NINDS
• Novartis
• Orion
• Oxford BioMedica
• Pacific Rainbow International
• Parkinson's UK
• Parr
• Pfizer
• Pharmacia
• Roche
• Roxane
• Sandoz
• Santhera
• Schering Plough
• Servier
• ShenZhou Biology & Technology
• Solvay Pharmaceuticals
• Sun Pharmaceuticals
• Synergen Corporation
• Synosia Therapeutics
• Teva Pharmaceutical Industries
• UCB
• University of Bristol Institute of Clinical Neuroscience
• University of Kentucky
• University of Nebraska
• University of Rochester
• Valeant
• Watson Pharmaceuticals
• Weill Medical College, Cornell University
• Wockhardt
• Xenoport
• Xiamen Kingdomway Group
• Zhejiang Medicine Company

相關商品

神經疾病相關市場調查報告書

中樞神經系統(CNS)的罕見疾病治療市場(∼2017年):AMR101和ACR16等新藥提供治療可供選擇，支援亨丁頓舞蹈症市場區隔
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
價格 : US $ 3500
出版日期 : 2012年04月

神經保護：醫療藥品・市場・企業
Neuroprotection - Drugs, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年04月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!